Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zuranolone in Parkinson's Disease
NCT03000569Phase 2Completed
- Sponsor
- Biogen
- Start
- Nov 2016
- Primary completion
- Sep 2017
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label trial of zuranolone in Parkinson's disease (PD) (2 arms), sponsored by Biogen. Primary endpoints: Treatment-emergent Adverse Events, Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part II/III Score at Day 14 and 6 more. Started Nov 2016; status: completed.
02
Drugs
zuranolone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03000569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03000569.